ME LD 1754 Veto Request Letter (2022)
A veto request of LD 1754, which sets new regulations on prior authorizations for contraceptives.
WV HB 4112 Veto Letter
PCMA submits comments requesting a veto of HB 4112, which imposes provisions relating to specialty pharmacies, 340b, and accreditation standards.
Indiana Comment Letter to BoP, DoH
PCMA submits comment letter to the Indiana BOP, DOH, and Oficce of Family and Social Services regarding a report looking at specialty drugs, their handling,
IA HF 729 Cost Analysis (2021)
If enacted, IA HF 729 would cost the state $1.2 billion over next 10 years. HF 729 would instittue Any Willing Provider rules and restrict
Specialty Pharmacy Accreditation Value Explainer (2021)
Explainer/One pager highlighting the value of Specialty Pharmacy Accreditation, by stakeholder.
PCMA Comment Letter MN RFI SF 278 (2019)
This comment letter was submitted by PCMA to the MN Department of Commerce regarding the implementation of SF 278 which was passed during the 2019
2019 SHAC Presentation: Specialty Pharmacy
This presentation from the 2019 SHAC Meeting highlights specialty pharmacy and the policy landscape.
URAC Comment Letter NY S.6531/A.2836 (2019)
This letter was submitted to New York Governor Andrew Cuomo in opposition to S.6531/A.2836 regarding the prohibition of accreditation by pharmacy benefit managers.
